Polyuria due to vasopressin V2 receptor antagonism is not associated with increased ureter diameter in ADPKD patients

BACKGROUND: Tolvaptan, a vasopressin V2 receptor antagonist, has been shown to reduce the rates of growth in total kidney volume (TKV) and renal function loss in ADPKD patients, but also leads to polyuria because of its aquaretic effect. Prolonged polyuria can result in ureter dilatation with conseq...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Clin Exp Nephrol
Main Authors: Casteleijn, Niek F., Messchendorp, A. Lianne, Bae, Kyong T., Higashihara, Eiji, Kappert, Peter, Torres, Vicente, Meijer, Esther, Leliveld, Anna M.
Formato: Artigo
Idioma:Inglês
Publicado: 2016
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5497698/
https://ncbi.nlm.nih.gov/pubmed/27339446
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10157-016-1297-1
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares